MarketPulse
B

$BBIO

4 articles found
2 positive
1 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Bridgebio Pharma, Inc.

BridgeBio's BBP-418 Shows Promise as First-Ever LGMD2I/R9 Treatment

BridgeBio reports positive Phase 3 results for BBP-418, showing 31-second improvement in walking tests. FDA submission expected H1 2026, potential U.S. launch late 2026/early 2027.
BBIOFDA approvaldrug development
BenzingaBenzinga··Vandana Singh

BridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.
PFEBBIOBMRNALNYregulatory approvaldrug development
BenzingaBenzinga··Nabaparna Bhattacharya

Large-Cap Selloff: Genuine Parts Leads Weekly Decline With Nearly 20% Drop

Large-cap stocks tumbled, with Genuine Parts dropping 19.51% after missing earnings expectations and cutting guidance. Nine other major companies also declined double-digits amid earnings disappointments.
OWLOKTATEAMEXPEGPC+4analyst downgradeslarge-cap losers
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BridgeBio Pharma Awards Equity Grants to 34 New Hires Under Nasdaq Rules

BridgeBio Pharma awarded 76,701 restricted stock units to 34 new employees as inducement grants under Nasdaq rules, vesting over four years with continued employment.
BBIOrestricted stock unitsvesting schedule